Real-World Benefits of Anti-CGRP mAbs for Migraine Relief

Research Summary

A study published in Neurology and Therapy explores the real-world use of anti-CGRP monoclonal antibodies (mAbs) for migraine prevention within a large U.S. healthcare network. The research involved 484 patients, primarily women aged 30-54, who completed a survey on their experiences. Results showed significant benefits for current users of anti-CGRP mAbs, with 62% reporting fewer headaches, improved functioning, and enhanced quality of life compared to past users. Persistence rates were high, with 74% continuing treatment for six months and 55% for a year. Current users also expressed higher satisfaction, highlighting the effectiveness of these treatments.

Study Details

📄 Title: Real-World Experience with Anti-CGRP Pathway Monoclonal Antibodies in a Large United States Healthcare Plan: Results of the Migraine Signature Study.

👥 Research Team: Buse DC et al.

📚 Published In: Neurol Ther

📅 Publication Date: 2025 Dec 17

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.